Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer - FTH News | Rallies
Faeth Therapeutics Announces FDA Grant Of Fast Track Designation For Piktor Plus Paclitaxel In Biomarker-Selected Advanced Endometrial Cancer F FTH • 2026-08-17 Upcoming trial data readouts
Faeth Therapeutics said topline data from its Phase 2 trial in advanced endometrial cancer is expected by year-end 2026 .
Interim data from its Phase 1b/2 trial in advanced breast cancer is expected in 2027 .
FDA fast track designation for Piktor Plus paclitaxel
Faeth Therapeutics, Inc. said the FDA granted Fast Track designation for Piktor Plus paclitaxel in biomarker-selected advanced endometrial cancer .
•
2026-08-17
FTH•
